natgillin/translations-raw huggingface dataset:
The method of claim 11, wherein the anxiety disorder is selected from the group consisting of panic attack, agoraphobia, panic disorder with agoraphobia, panic disorder without agoraphobia, agoraphobia without history of panic disorder, specific phobia, social phobia, obsessive-compulsive disorder, post-traumatic stress disorder, an acute stress disorder, generalized anxiety disorder, anxiety disorder due to general medical condition, substance-induced anxiety disorder, separation anxiety disorder, an adjustment disorder, performance anxiety, a hypochondriacal disorder, anxiety disorder due to general medical condition and substance-induced anxiety disorder. 
Primjena prema patentnom zahtjevu 22, naznačena time što su navedeni anksiozni poremećaji izabrani iz grupe koju čine anksioznost i poremećaji i bolesti povezani sa paničnim napadom, agorafobija, panični poremećaj sa agorafobijom, panični poremećaj bez agorafobije, agorafobija bez povijesti paničnih napada, specifična fobija, socijalna fobija i druge specifične fobije, opsesivno-kompulzivni poremećaj, post-traumatski stresni poremećaj, akutni stresni poremećaji, generalizirani anksiozni poremećaj, anksiozni poremećaj kao posljedica općeg medicinskog stanja, anksiozni poremećaj izazvan supstancom, anksiozni poremećaj odvajanja u djetinjstvu, poremećaji prilagođavanja, anksioznost pri javnom nastupu, hipohondrijski poremećaji, anksiozni poremećaj kao posljedica općeg medicinskog stanja i anksiozni poremećaj izazvan supstancom, i anksiozni poremećaj koji nije drugačije naznačen.
Examples of suitable organic acids include formic, acetic, trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric, fumaric, glycolic, itaconic, lactic, methanesulfonic, maleic, malic, malonic, mandelic, oxalic, picric, pyruvic, salicylic, succinic, methane sulfonic, ethanesulfonic, tartaric, ascorbic, pamoic, bismethylene salicylic, ethanedisulfonic, gluconic, citraconic, aspartic, stearic, palmitic, EDTA, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, p-toluenesulfonic acids, theophylline acetic acids, as well as the 8-halotheophyllines, for example 8-bromotheophylline and the like. 
Primjeri odgovarajućih organskih kiselina uključuju formičnu, octenu, trikloroctenu, trifluoroctenu, propionsku, benzoičnu, cinamičnu, limunsku, fumarnu, glikolnu, itakonsku, lactic, metansulfonsku, maleičnu, maličnu, maloničnu, bademsku, oksalnu, pikrinski, piruvinsku, salicilnu, sukcinsku, metan sulfoničnu, ctansulfonsku, tartaratnu, askorbinsku, pamoičnu, bismetilen salicilnu, etandisulfonsku, glukoničnu, citraconic, aspartansku, stearinsku, palmitinsku, EDTA, glikolnu, p-aminobenzoičnu, glutaminsku, benzensulfonsku, p-toluensulfonsku kiselinu, teofilinske octene kiseline kao i 8-haloteofilina, npr. 8-bromoteofilina i slično.
The instant coffee essentially comprises 
INSTANT KAVA SA TALOGOM
A combination comprising a lipidated tissue factor, thrombin, and fibrinogen. 
-o Kombinacija koja sadrži lipidirani tkivni faktor, trombin i fibrinogen.
catalytically converting syngas from said hydrogen-lean syngas stream via a Fischer-Tropsch reaction to produce hydrocarbons containing at least naphtha; 
katalitičkog prevođenja sinteznog plina iz navedene struje sinteznog plina siromašne vodikom Fischer-Tropschovom reakcijom kako bi se dobilo ugljikovodike koji u najmanju ruku sadrže naftu;
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) fenpropidin. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-diklorometiliden-benzonorbornen-5- iDamid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) fenpropidin.
is selected from the group consisting of H, C1-C6 alkyl and a nitrogen protecting group; wherein the nitrogen protecting group is selected from the group consisting of 9-fluorenylmethyloxycarbonyl, tert-butoxycarbonyl, carbobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl, acetyl, trifluoroacetyl, benzoyl, benzyl, p-methoxybenzyl, p-methoxyphenyl, 3,4-dimethoxybenzyl, triphenylmethyl, p-toluenesulfonyl, -C(O)OR31 and - C(O)R32; wherein 
R3 je odabran od skupine koja se sastoji od H, C;-Cg alkila 1 skupine koja štiti dušik; pri čemu je skupina koja štiti dušik odabrana od skupine koja se sastoji od 9-fluorenilmetiloksikarbonila, tertbutoksikarbonila, karbobenziloksikarbonila, p-metoksibenziloksikarbonila, acetila, trifluoroacetila, benzoila, benzila, p-metoksibenzila, p-metoksifenila, 3,4-dimetoksibenzila, trifenilmetila, p-toluensulfonila, -C(O)OR3; 1 - C(O)Rs2; pri čemu
The kit as claimed in claim 11, wherein the cotton is selected from the group consisting of natural cotton, surgical cotton, clinical grade cotton, commercial cotton, spun cotton, water washed cotton, acid or base washed cotton, autoclaved cotton, buffer treated cotton having a pH ranging from about 1 to about 14, salt solution treated cotton, organic solvent treated cotton, pressed cotton and processed cotton. 
Komplet u skladu s patentnim zahtjevom 11, naznačen time što se pamuk bira iz skupine koju čine prirodni pamuk, kirurški pamuk, pamuk kliničke kvalitete, komercijalni pamuk, predeni pamuk, pamuk pran vodom, pamuk pran kiselinom ili bazom, autoklavirani pamuk, puferirani pamuk s pH u rasponu od otprilike 1 do otprilike 14, pamuk obrađen otopinom soli, pamuk obrađen organskim otapalom, tiješteni pamuk i prerađeni pamuk.
In one embodiment of the present invention, the nucleic acid is either DNA or RNA. 
Metoda prema zahtjevu 12, pri čemu je nukleinska kiselina DNK ili RNA.
A compound of general formula (I) according to any one of claims 1 to 7 for the treatment and/or prophylaxis of lung carcinomas, prostate carcinomas, cervical carcinomas, colorectal carcinomas, melanomas, ovarian carcinomas or leukemias. 
Spoj s općom formulom (I) prema bilo kojem od zahtjeva 1 do 7, naznačen time da je za liječenje 1/ili profilaksu karcinoma pluća, karcinoma prostate, karcinoma grlića maternice, karcinoma debelog crijeva, melanoma, karcinoma jajnika ili leukemija.
The method of claim 1, wherein the first and second members of the dimerization pair are selected from the group consisting of: 
Heterodimerni, uvjetno aktivni CAR u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, da su prvi i drugi član dimerizacijskog para odabrani od sljedećih:
is a nucleofugic group or an optionally substituted aliphatic, aromatic, or heteroaromatic group; and 
je zaštitna grupa za amino grupu koja se može odvojiti; i X je OH ili odlazeća grupa;
Compound of formula (I) according to claim 1, wherein wherein R10 is as defined in claim 1. 
Spoj formule (I) u skladu s patentnim zahtjevom 1, naznačen time, da pri čemu je R10 kako je definiran u patentnom zahtjevu 1.
the home database of the public land mobile network is a Home Location Register and/or wherein the visitor database of the one service area out of the plurality of service areas of the public land mobile network is a Visitor Location Register, and that 
Metoda prema jednom od prethodnih zahtjeva, naznačena time da je polazna baza podataka (14) javne zemaljske mobilne mreže (10) jedan centralni registar podataka o pretplatnicima i/ili da je baza podataka o posjetiteljima (11) jednog od više servisnih područja javne zemaljske mobilne mreže (10) centralni registar podataka o posjetiteljima.
The dosage form of claim 2, wherein the content of rasagiline citrate is 0.74 mg to 3.63 mg, and which in addition to the rasagiline citrate, comprises mannitol, colloidal silicon dioxide, starch NF, pregelatinized starch, stearic acid, talc, hypromellose, methacrylic acid ethyl acrylate copolymer, talc extra fine, and triethyl citrate. 
Oblik doziranja prema patentnom zahtjevu 2, naznačen time, da je sadržaj rasagilin citrata od 0,74 mg do 3,63 mg i koji uz rasagilin citrat sadrži manitol, koloidni silicijev dioksid, škrob NF, prethodno želatinirani škrob, stearinsku kiselinu, talk, hipromelozu, kopolimer metakrilna kiselina - etil akrilat, ekstra fini talk i trietil citrat,
wherein is —C2-6alkylene-NR3R4, —C2-6alkylene-guanidine or —C2-6alkylene-COOH wherein each of R3 and R4 independently is H, C1-4alkyl, w-hydroxy-C2-4alkylene oracyl or R3 and R4 form together with the nitrogen atom to which they are attached a heterocyclic group which may comprise a further heteroatom, and 
R; i R; nezavisno H, C,aalkil, o-hidroksi-C,_jalkilen ili acil ili R; 1 Ry skupa s atomom dušika na kojeg su vezani čine heterocikličku skupinu koja može sadržavati daljnji heteroatom, te R2 je Z;-CH,-Rs, -CH>-CO-O-CH>-R;
It is especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for ease of administration and uniformity of dosage. 
Posebno je pogodno oblikovati gore spomenute farmaceutske pripravke u jedinični oblik za doziranje kako bi se olakšalo davanje i postigla ujednačenost doze.
The method of claim 1, wherein the anti-cancer agent is selected from the group consisting of radioisotopes, enzymes, prodrug activating enzymes, radiosensitizers, nucleic acid molecules, interfering RNAs, superantigens, anti-angiogenic agents, alkylating agents, purine antagonists, pyrimidine antagonists, plant alkaloids, intercalating antibiotics, aromatase inhibitors, anti-metabolites, mitotic inhibitors, growth factor inhibitors, cell cycle inhibitors, topoisomerase inhibitors, biological response modifiers, anti-hormones, toxins, photosensitizers, pyrimidine analogs, purine analogs, interferons, and non-steroidal anti-inflammatory drugs. 
Konjugat prema patentnom zahtjevu 7 ili patentnom zahtjevu 8, naznačen time što je fragment s terapeutskim djelovanjem član grupe koja se sastoji od radioizotopa, enzima, enzima koji aktiviraju prolijekove, radiosenzitajzera, interferirajućih RNK, superantigena, antiangiogenih sredstava, alkilirajućih sredstava, antagonista purina, antagonista pirimidina, biljnih alkaloida, interkalirajućih antibiotika, inhibitora aromataze, antimetabolita, inhibitora mitoze, inhibitora faktora rasta, inhibitora staničnog ciklusa, enzima, inhibitora topoizomeraze, modifikatora biološkog odgovora, antihormona i antiandrogena; ili
Sanding element according to any one of claims I to 11, characterised in that said lamellas (3,4) are fixed on a round, disc-shaped support (2), whereby the free edges (7) of these lamellas (3,4) extend almost radially. 
Element za brušenje u skladu s bilo kojim od patentnih zahtjeva 1 do 11, naznačen time, što su navedene lamele (3, 4) pričvršćene na okrugli nosač koja ima oblik diska (2), pri čemu se slobodni rubovi (7) tih lamela (3,4) pružaju gotovo radijalno.
The box-shaped collar is also provided with means used to adjust its fastening position with respect to the box in order to ensure the perfect co-planarity of the collar front edges with the wall where the box is recessed. 
Okvir koji ima oblik kutije je također snabdjeven sa sredstvima koja se koriste za namještanje njegovog položaja pri učvršćivanju u odnosu na kutiju, da bi se na taj način osigurala savršene ravnina prednjih rubova okvira sa zidom u koji se umeće kutija.
administering to the subject a primary vaccination series of four to six monthly intradermal injections of a vaccine composition comprising a peptide having the amino acid sequence of SEQ ID NO: 2; and, administering to the subject a booster composition comprising a peptide having the amino acid sequence of SEQ ID NO: 2 about 6 months after completion of the primary vaccination series. The method of any one of claims 1 - 4, wherein the vaccine composition comprises about 0.1 mg to about 10 mg of the peptide. 
NO:2, 1 0.125 ili 0.250 mg humanog stimulirajućeg faktora kolonije granulocita/makrofaga (GM-CSF) kao adjuvanta, pri čemu je pripravak cjepiva formuliran za davanje kao tri do šest mjesečnih injekcija, poželjno kao intradermalne injekcije; te (1i) pripravak booster cjepiva koji sadrži 1 mg peptida koji sadrži sekvencu amino kiseline SEQ ID NO:2, 1 0.125 ili 0.250 mg humanog stimulirajućeg faktora kolonije granulocita/makrofaga (GM-CSF) kao adjuvanta, pri čemu je pripravak booster cjepiva formuliran za davanje pomoću injekcije, poželjno intradermalne injekcije, svakih šest mjeseci nakon završetka primarne imunizacije.
Substitutions and deletions* 
supstitucije i delecije"
Package according to claim 18, characterised in that the reinforcement insert is formed as a plastic container, preferably made by injection-moulding. 
Omot za pakiranje u skladu s patentnim zahtjevom 15, naznačen time što je pojačani umetak načinjen kao plastični spremnik, za koji je poželjno da je načinjen pomoću lijevanja injektiranjem.
In addition, the pharmaceutical forms nowadays used, although they permit the administration of the active ingredient in discrete doses, release it too rapidly in relation to the time taken to pass through the digestive tract, so that the active ingredient performs its anti-infectious activity in an indiscriminate manner along the entire gastro-intestinal tract. 
Dodatno, danas upotrebljavani farmaceutski pripravci, iako omogućavaju davanje aktivnog sastojka u odredenim dozama, oslobađaju isti jako brzo u odnosu na vrijeme koje je potrebno da sastojak prođe kroz probavni sustav, tako da aktivni sastojak djeluje antiinfektivno kroz cijeli gastro-intestinalni trakt i to na neodređen način.
The amount of sucrose or lactose (135 g) was added and the mixture was stirred for an additional period of approximately 1h until dissolution. 
Količina saharoze ili laktoze (135 g) je dodana i smjesa je miješana za dodatni vremenski period od približno 1 sat do otapanja.
The antibody or antibody fragment according to claim 12, wherein the disease is selected from the group consisting of an allergic disease, asthma, cancer, an autoimmune disease, scleroderma and idiopathic pulmonary fibrosis. 
Bispecifično protutijelo ili fragment protutijela za uporabu prema zahtjevu 14, naznačeno time da je bolest odabrana iz skupine koju čine alergijska bolest, astma, rak, autoimuna bolest, sklerodermija i idiopatska plućna fibroza.
A scaffold according to claim 1 wherein the matrix of interconnected growth surfaces spaced at regular intervals are formed around a central support. 
Uređaj u skladu s patentnim zahtjevom 1 pri čemu je podij oblikovan matriksom međusobno povezanih površina rasta razmaknutih u pravilnim intervalima oko središnje potpore.
In certain embodiments, a carboxylate salt of the compound of formula (I) is employed, such as the triethylammonium (TEA) or potassium salt. 
Pripravak u skladu s patentnim zahtjevom 1, naznačen time što je (a) metilni ester, trietilamonijeva (TEA) sol ili kalijeva sol spoja formule (I).
adjusting the pH of the eluate from the Zn-chelating Sepharose FF capture column filtrate from step c) to about pH 4.5 ± 0.1, and filtering the pH 4.5-adjusted eluate from the Zn-chelating Sepharose FF capture column filtrate; 
podešavanje pH eluata iz filtrata iz Zn-kelirajućeg stupca Sepharose FF capture iz koraka c) do oko pH 4.5 ± 0.1, i filtriranje eluata s podešenim pH na 4.5 iz filtrata iz Zn-kelirajućeg stupca Sepharose FF capture;
The IL-18BP gene was localized to the human chromosome 11q13, and no exon coding for a transmembrane domain was found in an 8.3kb genomic sequence. 
Gen zaIL-18BP lokaliziranje na humanom kromosomu Ilql3, te nije pronađen ekson koji kodira za transmembransku domenu unutar 8,3 kb velikog genomskog slijeda.
reacting the compound of formula (X-E) with a compound of formula (XII); in the presence of a first inorganic base; in an organic solvent; or 
alternativno, reakciju spoja s formulom (XI-S) sa spojem s formulom (VI-S), pri čemu LG1 je prva izlazna skupina i LG2 je druga izlazna skupina; u prisutnosti baze; u smjesi vode i organskog otapala;
The immunogenic composition of claim 6 further comprising at least two optimized env viral polypeptides, wherein said polypeptides comprise an amino acid sequence having the sequences set forth in each of SEQ ID NO:9 and 10. 
121 13, respektivno; Cjepivo prema zahtjevu 5 ili 6, gdje spomenuto cjepivo nadalje sadrži vektor koji kodira optimizirani env polipeptid koji ima sekvencu prikazanu u SEQ ID NO: 10.
The compound or salt of claim 67 wherein at least one mutation of said mutant JAK2 resides in the pseudo-kinase domain of said JAK2. 
Spoj ili sol prema zahtjevu 67 naznačen time da barem jedna mutacija navedene mutirane JAK2 nalazi se u domeni pseudo-kinaze navedene JAK2.
a container that contains a pharmaceutical composition containing a peptide according to any one of claims 1 to 4, the nucleic acid or the expression vector according to claim 5, a cell according to claim 7, or an activated cytotoxic T lymphocyte according to claim 10, in solution or in lyophilized form; 
posudu koja sadrži farmaceutski sastav koji sadrži peptid u skladu s bilo kojim od patentnih zahtjeva od 1 do 4, stanicu u skladu s patentnim zahtjevom 7 ili aktivirani citotoksični T limfocit u skladu s patentnim zahtjevom 10, u otopini ili u liofiliziranom obliku;
providing a second web (172) having a series of parallel grooves with a three-sided polygonal cross section; and, 
(ii) osiguravanje druge mreže (172) s nizom paralelnih žljebova s poligonalnim trostranim poprečnim presjekom; i
A coating composition as claimed in any preceding claim wherein the coating composition comprises from about 40 to about 55% of the flour component by dry weight. 
Postupak prema patentnim zahtjevima 1 ili 2, naznačen time što je količina modificiranog škroba u kompoziciji za oblaganje 15 do 50% prema suhoj težini.
The polypeptide of any one of claims 1 to 6 for the prevention of CDAD in a subject at risk of a CDAD. 
Polipeptid ili sastav za uporabu iz patentnog zahtjeva 9, za uporabu u prevenciji CDAD kod subjekta s rizikom od CDAD.
This and other compounds having a benzamide structure and their use as cyclic nucleotide phosphodiesterase (PDE) inhibitors are described in WO95/01338. 
Ovaj i ostali spojevi koji imaju benzamidnu strukturu i njihova uporaba kao inhibitora cikličke nukleotid fosfodiesteraze (PDE) su opisani u WO95/01338.
The use of a kit in the diagnosis of Graft versus Host Disease, GVHD, said kit comprising a protein chip comprising an array of bound antibodies recognizing biomarkers characteristic of GVHD, said biomarkers are selected from the group comprising Total GSK-3B, serine 9 phosphorylated GSK-3B, GSK-3B serine 9 phosphorylation PKC activation, GSK-3B tyrosine 216 phosphorylation, for determining the expression levels of different GVHD relevant proteins in a given sample. 
Korištenje kompleta u dijagnozi Graft versus Host Disease, GVHD, pri čemu navedeni komplet sadrži proteinski čip koji sadrži niz vezanih protutijela koja prepoznaju biomarkere karakteristične za GVHD, pri čemu su navedeni biomarkeri odabrani iz skupine koja obuhvaća Total GSK3f, serin 9 fosforiliran GSK-3f, PKK aktivaciju fosforilacije GSK-3f serina 9, fosforilacija GSK-3f: tirozina 216, za određivanje razina ekspresije različitih GVHD relevantnih proteina u danom uzorku.
a circular membrane for closing the opening which is sealed onto the flange-like rim, 
– kružne membrane (6) za zatvaranje otvora, koja je zavarena na rub koji služi kao prirubnica;
C1-10 alkoxy, wherein alkoxy is optionally substituted with one to five substituents independently selected from fluorine and hydroxy, 
-10 alkoksi, gdje je alkoksi izborno supstituiran sa jednim do pet supstituenata nezavisno izabranih od fluora i hidroksi,
In accordance with a general embodiment of the present invention, a propulsion assembly of a ship, or a floating platform, comprises a hull insert forming a housing, or propeller case, arranged within a hull of said ship or platform. 
Sklop broda ili porivne plutajuće platforme (1), obuhvaća - umetak trupa (2), ili sanduk, koji formira kućište (3), ili spremnik propelera, smješten unutar trupa (4) broda ili platforme;
A compound of any one of claims 1-9, wherein the compound has hMGAT2 IC50 values ≤ 0.1 µM, using the MGAT2 LCMS assay. 
Spoj iz bilo kojeg od patentnih zahtjeva 1-9, gdje spoj ima hMGAT2 ICs, vrijednosti < 0.1 uM, korištenjem MGAT?2 LCMS testa.
The vertically expanding bag (1900) of claim 1, further comprising a bottom surface in the cavity or pocket (2010) formed by the non-collapsible side walls, the bottom surface separating the non-collapsing cavity or pocket (2010) from the collapsible pocket (2011). 
Torba koja se može izduljiti po visini (1900) prema zahtjevu 1, koja dalje obuhvaća donju podlogu u šupljini 1li džepu (2010) koji formiraju nesklopive bočne stijenke, s tim da donja podloga odvaja nesklopivu šupljinu ili džep (2010) od sklopivog džepa (2011).
The composition of claim 5, for use in the treatment of CMT1A in a mammalian subject. 
Sastav 1z patentnog zahtjeva 5, za uporabu u liječenju CMTIA u subjekta sisavca.
The method of claim 99, wherein said thiazolidinedione is rosiglitazone or pioglitazone, or combination thereof. 
navedeni tiazolidindion je rosiglitazon ili pioglitazon, ili njihova kombinacija;
The method of claim 14 further comprising administering to the patient an additional therapeutic agent selected from 5-FU, docetaxel, eribulin, gemcitabine, cobimetinib, ipatasertib, paclitaxel, tamoxifen, fulvestrant, GDC-0810, dexamethasone, palbociclib, bevacizumab, pertuzumab, trastuzumab emtansine, trastuzumab and letrozole. 
Spoj za uporabu prema patentnom zahtjevu 14, naznačen time, da nadalje obuhvaća davanje pacijentu dodatnog terapeutskog agensa odabranog između 5-FU, docetaksela, eribulina, gemcitabina, kobimetiniba, ipatasertiba, paklitaksela, tamoksifena, fulvestranta, GDC-0810, deksametazona, palbocikliba, bevacizumaba, pertuzumaba, trastuzumab emtanzina, trastuzumaba i letrozola.
A compound of formula (Ia): or a pharmaceutically acceptable salt thereof, wherein: 
Spoj s formulom (Ia): [image] ili njegova farmaceutski prihvatljiva sol, pri čemu: n je 0, 1 ili 2;
is unsubstituted phenyl, or a stereoisomer of the compound. 
R5 je nesupstituirani fenil, ili stereoizomer toga spoja.
The pharmaceutical composition of claim 1 or 2, wherein a flat dose of 5 µg/m2/d of the CD3 binding domain is administered for up to 8 weeks. 
Glukokortikoid za uporabu u skladu s patentnim zahtjevom 1 ili 2, pri čemu se CD3 vezna domena primjenjuje neprekidno.
reacting a compound of formula II 
(A) reakciju spoja formule II
Chemically modified heparin for use according to claims 1 or 2, wherein at least 30 % of the polysaccharide chains have a molecular weight of at least 8 kDa. 
Kemijski modificiran heparin prema zahtjevima 1 ili 2, naznačen time da najmanje 30% polisaharidnih lanaca ima molekularnu masu od najmanje $ kDa.
Use of a compound of the formula [I] of claim 24 or a pharmaceutically acceptable salt thereof as an active ingredient for the production of an antitumor agent. Use of a compound of the formula [I] of claim 24 or a pharmaceutically acceptable salt thereof as an active ingredient for the production of a pharmaceutical agent capable of inhibiting MEK. 
Upotreba spoja formule [I] u skladu s patentnim zahtjevom 24, ili njegove farmaceutski prihvatljive soli, naznačena time što je spoj formule [I] aktivni sastojak u proizvodnji farmaceutskog sredstva koje može inhibirati MEK.
a contiguous sequence of the human λ light chain locus that spans from hVλ5-52 through hVλ1-40 and a contiguous sequence of the human λ light chain locus that spans from hVλ3-29 through hVλ3-1. 
graničnu sekvenciju humanog lokusa lakog λ lanca koja se proteže od hVλ5-52 do hVλ1-40 i graničnu sekvenciju humanog lokusa lakog λ lanca koja se proteže od hVλ3-29 do hVλ3-1.
Use of Claim 57, wherein the dose of the IL-17 antagonist in the pharmaceutical composition is gradually reduced during a second treatment period that begins upon the end of the first treatment period. 
Uporaba u skladu sa zahtjevom 57, naznačena time, da se doza IL-17 antagonista u farmaceutskom pripravku postupno smanjuje za vrijeme drugog razdoblja liječenja koje započinje završetkom prvog razdoblja liječenja.